Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
BörsenkürzelDNA
Name des UnternehmensGinkgo Bioworks Holdings Inc
IPO-datumApr 19, 2021
CEOKelly (Jason)
Anzahl der mitarbeiter834
WertpapierartOrdinary Share
GeschäftsjahresendeApr 19
Addresse27 Drydock Avenue
StadtBOSTON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl02210
Telefon18774425362
Websitehttps://investors.ginkgobioworks.com/
BörsenkürzelDNA
IPO-datumApr 19, 2021
CEOKelly (Jason)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten